CA2395108A1 - Method of treating gastrointestinal tract disease with purinergic receptor agonists - Google Patents
Method of treating gastrointestinal tract disease with purinergic receptor agonists Download PDFInfo
- Publication number
- CA2395108A1 CA2395108A1 CA002395108A CA2395108A CA2395108A1 CA 2395108 A1 CA2395108 A1 CA 2395108A1 CA 002395108 A CA002395108 A CA 002395108A CA 2395108 A CA2395108 A CA 2395108A CA 2395108 A1 CA2395108 A1 CA 2395108A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- substituted
- group
- amino
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17171099P | 1999-12-22 | 1999-12-22 | |
US60/171,710 | 1999-12-22 | ||
PCT/US2000/035439 WO2001045691A2 (en) | 1999-12-22 | 2000-12-22 | Method of treating gastrointestinal tract disease with purinergic receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2395108A1 true CA2395108A1 (en) | 2001-06-28 |
Family
ID=22624842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002395108A Abandoned CA2395108A1 (en) | 1999-12-22 | 2000-12-22 | Method of treating gastrointestinal tract disease with purinergic receptor agonists |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1261323A2 (ko) |
JP (1) | JP2003524636A (ko) |
KR (1) | KR20020069218A (ko) |
CN (1) | CN1413113A (ko) |
AU (1) | AU2603101A (ko) |
BR (1) | BR0016021A (ko) |
CA (1) | CA2395108A1 (ko) |
MX (1) | MXPA02005161A (ko) |
WO (1) | WO2001045691A2 (ko) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629329B2 (en) | 2001-06-04 | 2009-12-08 | Tsi Health Sciences, Inc. | Method for increasing muscle mass and strength through administration of adenosine triphosphate |
WO2003039473A2 (en) * | 2001-11-06 | 2003-05-15 | Inspire Pharmaceuticals, Inc. | Method for treating or preventing inflammatory diseases |
US7049303B2 (en) | 2001-11-07 | 2006-05-23 | Medical Research Council | Inhibition of viruses |
US7732487B2 (en) * | 2001-11-19 | 2010-06-08 | Sucampo Ag | Method for treating a disease or condition responsive to opening of C1C-2 channel |
EP1348466A3 (en) | 2002-02-01 | 2003-10-29 | Inspire Pharmaceuticals, Inc. | Method for treating pain with adenosine-tetraphosphates |
US6683060B2 (en) * | 2002-02-25 | 2004-01-27 | Advanced Gene Technology Corp. | Matrix metalloproteinase and tumor necrosis factor inhibitors |
EP1485395A4 (en) | 2002-02-28 | 2011-04-13 | Biota Scient Management | NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF |
GB0312844D0 (en) * | 2003-06-04 | 2003-07-09 | Paradigm Therapeutics Ltd | Use of compounds in medicine |
KR101133944B1 (ko) * | 2004-06-28 | 2012-04-13 | 아지노모토 가부시키가이샤 | 영양 조성물 및 소화관 기능 저하 예방?개선용 조성물 |
EP1806134B1 (en) * | 2004-09-17 | 2012-07-11 | Ajinomoto Co., Inc. | Agent and food for preventing/improving functional digestive disorder |
JP5408882B2 (ja) * | 2008-01-23 | 2014-02-05 | ヤマサ醤油株式会社 | 唾液分泌促進剤 |
GB201320962D0 (en) * | 2013-11-27 | 2014-01-08 | Globalacorn Ltd | Compositions |
GB201320959D0 (en) * | 2013-11-27 | 2014-01-08 | Globalacorn Ltd | Compositions |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7395094A (en) * | 1993-10-15 | 1995-05-04 | Wisconsin Alumni Research Foundation | Substituted purine nucleoside analogs and method for treating endotoxin shock |
US5837861A (en) * | 1997-02-10 | 1998-11-17 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
PT981534E (pt) * | 1997-02-06 | 2006-09-29 | Inspire Pharmaceuticals Inc | Dinucleotidos e suas utilizacoes |
CA2359891A1 (en) * | 1999-02-26 | 2000-08-31 | Inspire Pharmaceuticals, Inc. | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
-
2000
- 2000-12-22 KR KR1020027007963A patent/KR20020069218A/ko not_active Application Discontinuation
- 2000-12-22 MX MXPA02005161A patent/MXPA02005161A/es unknown
- 2000-12-22 CA CA002395108A patent/CA2395108A1/en not_active Abandoned
- 2000-12-22 JP JP2001546630A patent/JP2003524636A/ja active Pending
- 2000-12-22 WO PCT/US2000/035439 patent/WO2001045691A2/en not_active Application Discontinuation
- 2000-12-22 EP EP00989533A patent/EP1261323A2/en not_active Withdrawn
- 2000-12-22 CN CN00817607A patent/CN1413113A/zh active Pending
- 2000-12-22 AU AU26031/01A patent/AU2603101A/en not_active Abandoned
- 2000-12-22 BR BR0016021-0A patent/BR0016021A/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2001045691A3 (en) | 2002-04-18 |
EP1261323A2 (en) | 2002-12-04 |
BR0016021A (pt) | 2003-07-15 |
AU2603101A (en) | 2001-07-03 |
JP2003524636A (ja) | 2003-08-19 |
KR20020069218A (ko) | 2002-08-29 |
MXPA02005161A (es) | 2002-12-09 |
WO2001045691A2 (en) | 2001-06-28 |
CN1413113A (zh) | 2003-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6624150B2 (en) | Method of treating gastrointestinal tract disease with purinergic receptor agonists | |
KR100606131B1 (ko) | 디뉴클레오티드 및 그의 용도 | |
US5837861A (en) | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency | |
CA2395108A1 (en) | Method of treating gastrointestinal tract disease with purinergic receptor agonists | |
CA2748057C (en) | Nucleoside phosphoramidates | |
IL267291B2 (en) | Actonucleotidase inhibitors and methods of using them | |
CA2352262A1 (en) | Method of promoting cervical and vaginal secretions | |
US6864243B1 (en) | Method for treating retinal degeneration with purinergic receptor agonists | |
US6555675B2 (en) | Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists | |
JP2005532254A (ja) | 炎症性疾患を治療又は予防する方法 | |
JPWO2018199048A1 (ja) | ヌクレオシド系抗がん剤または抗ウィルス剤の5’位モノ燐酸ジベンジルエステル誘導体 | |
WO2006016115A2 (en) | Method and means for enhanced pulmonary drug delivery | |
JP2002528510A (ja) | HIV感染の治療のためのβ−L−2’−デオキシ−ヌクレオシド | |
MXPA99007236A (en) | Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |